The SURMOUNT-4 randomized clinical trial assessed the effect of tirzepatide discontinuation on the maintenance of weight reduction in adults with obesity and a weight-related complication, excluding diabetes
While initial clinical trials have reported encouraging average weight loss results, they have also highlighted possible common side effects similar to those seen with GLP-1 agonists, such as: Currently, Retatrutide is not legal for sale or prescription in the UK
The intervention led to significant effects as shown by the significant treatment visit interactions observed in all the glycemia related biomarkers and the significant differences between groups in the rate of change of FBG and HbA1c (Table 2), which showed opposite directions during the intervention, decreasing in MO and increasing in PLC
All that remains to be seen, and an absolute benefit of 1.5 per 100 people treated is certainly nothing to write home about
Is there any further information about that
HPO Axis: Hypothalamic action on GnRH/kisspeptin cuts pathological LH hypersecretion
